Piramal Pharma Ltd (PPLPHARMA)
₹238.91
Mkt cap
₹31,807 Cr
P/E ratio
—
P/B
3.90
Div yield
0.00%
ROE
−3.83%
ROCE
2.52%
EPS (TTM)
—
Book value
₹61
52W range
132–240
Sector
Healthcare
Price history
Previous close
Piramal Pharma Limited (PPL) is part of the Piramal group of companies. The company operates through 3 major segments (1) Contract development and manufacturing organisations (CDMO), (2) Complex hospital generics (critical care), and (3) consumer healthcare (OTC). Company entered Pharma space back in 1988 with acquisition of Nicholas Laboratories and grew through a series of Mergers & Acquisitions [1] and various organic initiatives. In 2010 the Domestic formulations business was sold to Abott for $3.7 billion [2] and Diagnostic Services was sold to Super Religare Laboratories (SRL) [3]
NSE PPLPHARMABSE 543635
Health check
Mixed
ProfitabilityWeak
GrowthModerate
TechnicalsBullish
52-week range
−0.45% from high₹239
₹132+80.58% from low₹240
Current
₹238.91
Prev close
₹230.78
Day
+3.52%
Price performance
1D
+3.13%
1W
+24.56%
1M
+13.84%
3M
+20.98%
6M
+48.61%
1Y
+16.90%
YTD
+33.86%
Financials
Revenue, profit & margin
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,911.38 | 1,958.57 | 2,552.36 | 1,951.14 | 2,241.75 | 2,204.22 | 2,754.07 | 1,933.71 | 2,043.72 | 2,139.87 | 2,751.77 | 2,269.92 | 2,617.06 | |
| Expenses | 1,645.74 | 1,690.20 | 2,022.43 | 1,746.65 | 1,900.14 | 1,866.48 | 2,193.08 | 1,827.01 | 1,885.03 | 1,944.14 | 2,291.26 | 2,074.72 | 2,268.32 | |
| Operating Profit | 265.64 | 268.37 | 529.93 | 204.49 | 341.61 | 337.74 | 560.99 | 106.70 | 158.69 | 195.73 | 460.51 | 195.20 | 348.74 | |
| OPM % | 13.90% | 13.70% | 20.76% | 10.48% | 15.24% | 15.32% | 20.37% | 5.52% | 7.76% | 9.15% | 16.74% | 8.60% | 13.33% | |
| Other Income | 68.30 | 43.19 | 7.90 | 41.94 | 78.37 | 29.18 | 58.25 | 97.71 | 80.39 | 12.39 | -116.14 | 108.97 | 53.67 | |
| Interest | 109.87 | 105.88 | 114.22 | 106.96 | 107.64 | 103.31 | 103.68 | 86.15 | 82.42 | 89.24 | 82.99 | 88.08 | 87.63 | |
| Depreciation | 184.51 | 186.32 | 196.13 | 184.55 | 192.22 | 196.81 | 242.76 | 197.28 | 202.84 | 212.74 | 218.38 | 223.55 | 233.15 | |
| Profit before tax | 39.56 | 19.36 | 227.48 | -45.08 | 120.12 | 66.80 | 272.80 | -79.02 | -46.18 | -93.86 | 43.00 | -7.46 | 81.63 | |
| Tax % | 87.31% | 47.78% | 55.48% | 96.63% | 81.19% | 94.49% | 43.73% | 3.39% | 114.85% | 45.10% | 120.53% | 830.16% | 93.84% | |
| Net Profit | 5.02 | 10.11 | 101.27 | -88.64 | 22.59 | 3.68 | 153.50 | -81.70 | -99.22 | -136.19 | -8.83 | -69.39 | 5.03 | |
| EPS in Rs | 0.04 | 0.08 | 0.77 | -0.67 | 0.17 | 0.03 | 1.16 | -0.61 | -0.75 | -1.02 | -0.07 | -0.52 | 0.04 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move +2.23% · closed higher next day 7 of last 17
| Q3FY24 | Q4FY24 | Q1FY25 | Q2FY25 | Q3FY25 | Q4FY25 | Q1FY26 | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 | Q2FY27 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Broadcast | 30 Jan '24◦ | 10 May '24◦ | 26 Jul '24 | 23 Oct '24◦ | 28 Jan '25◦ | 14 May '25◦ | 28 Jul '25◦ | 5 Nov '25◦ | 29 Jan '26 | 28 Apr '26◦ | 29 Jul '26◦ | 27 Oct '26◦ |
| Earnings day | +3.78% | +2.49% | +0.13% | +17.36% | +9.49% | −4.76% | +0.62% | −0.54% | −0.18% | −2.63% | +0.53% | +17.15% |
| +1 day | −0.47% | −1.03% | +2.39% | +12.13% | +5.81% | −6.47% | −1.46% | −0.63% | +0.47% | −1.58% | −0.04% | +16.13% |
| +5 days | +0.25% | −0.63% | +4.79% | +23.16% | +3.88% | −5.81% | −5.29% | −3.28% | +3.01% | +11.71% | +6.42% | — |
| +15 days | −2.95% | −0.56% | +10.29% | +15.49% | −9.56% | −5.00% | −6.15% | −7.00% | +5.90% | +7.06% | +10.72% | — |
| +30 days | −14.06% | +6.18% | +30.69% | +18.81% | −7.65% | −8.24% | −2.05% | −16.91% | −9.19% | −0.38% | +8.59% | — |
| Filing | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL |
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
as of Sep 202634.80%Promoter
Promoters34.80%
FIIs13.65%1.14
DIIs14.43%0.14
Public36.72%0.90
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,777.70 | 34.66 | 4,26,530 | 0.90% | 1,995 | −10.53% | 16,199 | +11.88% | 20.53% |
| Divi's Lab. | ₹9,780.00 | 87.14 | 2,59,628 | 0.31% | 902 | +65.50% | 3,080 | +27.80% | 21.97% |
| Torrent Pharma. | ₹4,613.40 | 80.83 | 1,75,479 | 0.82% | 534 | −10.03% | 4,979 | +50.79% | 15.19% |
| Laurus Labs | ₹2,405.50 | 97.00 | 1,29,972 | 0.08% | 436 | +126.43% | 2,206 | +33.44% | 17.76% |
| Zydus Lifesci. | ₹1,245.50 | 25.52 | 1,24,239 | 0.08% | 990 | −35.09% | 8,017 | +21.96% | 21.14% |
| Dr Reddy's Labs | ₹1,352.00 | 40.30 | 1,12,849 | 0.59% | 913 | −31.35% | 8,698 | −1.48% | 13.04% |
| Cipla | ₹1,378.90 | 35.87 | 1,11,397 | 0.94% | 852 | −35.05% | 7,404 | −2.44% | 15.49% |
| Piramal Pharma | ₹238.91 | — | 31,807 | 0.00% | 5 | +105.62% | 2,617 | +28.05% | 2.52% |
| Median: 158 Co. | ₹426.38 | 34.03 | 1,921 | 0.08% | 14 | +24.68% | 175 | +19.54% | 15.12% |
Filings
Concall transcripts50
PPTOct 2026RECOct 2026TranscriptJul 2026PPTJul 2026RECJul 2026TranscriptApr 2026PPTApr 2026RECApr 2026TranscriptJan 2026PPTJan 2026TranscriptNov 2025PPTNov 2025TranscriptOct 2025PPTJul 2025RECJul 2025PPTJul 2025TranscriptMay 2025PPTMay 2025TranscriptFeb 2025PPTFeb 2025RECFeb 2025TranscriptOct 2024PPTOct 2024PPTSep 2024
Credit ratings6
Announcements5
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 31 Oct - HDFC Mutual Fund reduced Piramal Pharma holding from 7.015% to 4.988% on October 28, 2026.Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 30 Oct - Intimation of Schedule of Analyst/ Institutional Investor Meetings under the SEBI LODR Regulations, 2015Announcement under Regulation 30 (LODR)-Earnings Call Transcript 30 Oct - Details of Earning call Transcript held on 28th October 2026.Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome 28 Oct - Audio recording of 28 October 2026 results conference call for Q2 and half year ended 30 September 2026.Unaudited Financial Results (Standalone And Consolidated) Of The Company For The Quarter Ended September 30, 2026 27 Oct